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Acute myeloid leukemia (AML) with deranged core-binding factor beta (CBFb) is usually associated with a
favorable prognosis with 50–70% of patients cured using contemporary treatments. We analyzed the prog-
nostic significance of clinical features on 58 patients with CBFb-AML aged 60 years. Increasing age was the
only predictor for survival (P <0.001), with an optimal cut-point at 43 years. White blood cells (WBCs) at diag-
nosis emerged as an independent risk factor for relapse incidence (P50.017), with 1.1% increase of hazard
for each 1.0 3 109/L WBC increment. KIT mutations lacked prognostic value for survival and showed only a
trend for relapse incidence (P50.069). Am. J. Hematol. 88:594–600, 2013. VC 2013 Wiley Periodicals, Inc.
Introduction
Among acute myeloid leukemias (AMLs) with recurrent
genetic abnormalities, patients with t(8;21)(q22;q22),
inv(16)(p13q22), or t(16;16)(p13;q22), are referred to as
core-binding factor (CBF)-AML. Although CBF-AML patients
share a common molecular pathogenetic event, nominally
the creation of a fusion protein involving a CBF gene unit,
these two types of AML differ with regard to morphologic
presentation, immunophenotypic marker expression, prog-
nostic factors, and response to treatments, and should be
considered as distinct clinical entities [1,2].
In the inv(16)/t(16;16) group, the CBF-beta (CBFb)
gene located on 16q22 fuses to the MYH11 gene on
16p13, resulting in a chimeric protein. The translocation
t(16;16)(p13;q22) is an equivalent rearrangement with lower
incidence. Cytogenetically, the CBFb–MYH11 rearrange-
ment may be associated with trisomies of the chromosomes
8, 21, and 22 or with deletion of the chromosome 7 [3,4].
Patients with CBFb-AML account for about 5–8% of adults
with de novo AML and they are frequently associated with
specific characteristics. This AML subset is morphologically
associated with the French–American–British (FAB) M4 sub-
type with an abnormal eosinophil component (M4eo) and
extramedullary involvement may be present [3–9].
Clinically, patients with CBFb-AML are closely associated
with a favorable outcome as compared with other AML sub-
types [10–15]. High-complete remission (CR) rate and pro-
longed disease-free survival may be achieved when patients
are treated with standard induction therapy followed by high-
dose cytarabine (HD-AraC) post-remission therapies [16].
Despite these results, the outcome of CBFb-AML patients
does not appear to be as homogeneous as their cytogenetic
definition, because only 54–74% are cured using contempo-
rary treatment [17]. Recurrent disease occurs in 30–40% of
patients, with a significant number of them subsequently
dying from disease progression. Prognostic factors of
relapse risk in CBFb-AML subset are still a matter of
debate. Female gender, older age, and low-platelet count
have been reported as predictors for inferior outcome and/or
shorter disease-free survival in patients enrolled in prospec-
tive trials [1,17,18]. Furthermore, higher white blood cells
(WBCs) and low-platelet counts have been identified as bad
predictor factors for CR achievements [19,20]. Conversely,
nonrandom additional cytogenetic abnormalities such as tris-
omy 122, and male sex predicted better outcome [1,21].
Gene mutations represent novel prognostic markers in
CBFb-AML. The most common gene mutations in the
inv(16)/t(16;16) group are those involving the KIT gene,
that are observed approximately in 20–30% of patients
[22–24]. Retrospective studies have demonstrated that the
presence of KIT mutations in exon 17 have been associ-
ated with a poor outcome in CBF-AML and, for that reason,
KIT mutation testing has been recently incorporated into
National Cancer Guidelines to better stratify such patients
in different prognostic subgroups [25]. However, while sev-
eral studies showed that activating KIT mutations confer a
significantly lower survival in AML with t(8;21)(q22;q22),
the negative prognostic impact of KIT mutations in CBFb-
AML remains controversial [24,26–33].
In this study, we analyze the prognostic significance of
clinical and genetic features such as age, gender, WBC
count, presence of extramedullary leukemia (EML), addi-
tional cytogenetic abnormalities, and KIT mutations on
long-term outcome of a large group of adult patients with
inv(16)/t(16;16). Our results indicate that increasing age is
the best predictor for survival of CBFb-AML patients aged
less than or equal to 60 years at univariate and multivariate
analysis. Interestingly, KIT mutations lack prognostic value
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in terms of both survival and relapse incidence (RI). This
result contrasts with the observation done in AML with
t(8;21)(q22;q22), suggesting differences in biology of CBF-
AMLs.
Design and Methods
Patients’ characteristics, data collection,
and treatment protocols
Fifty-eight patients aged less than or equal to 60 years with
untreated AML presenting inv(16)(p13q22) or t(16;16)(p13;q22)
diagnosed in eight Italian centers were included in this study
(see Table I for patients’ characteristics).
Each patient gave his/her informed consent for collection
of clinical data, the cryopreservation of bone marrow sam-
ples, and the performance of DNA-analysis for scientific
purposes, in accordance with institutional guidelines.
Bone marrow samples from each patient were collected
and cryopreserved at diagnosis and then centrally analyzed
for KIT gene mutational status at the Department of Biology
and Genetics for Medical Sciences, University of Milan, Italy.
For each patient, data regarding hematologic parame-
ters, bone marrow morphology, immunophenotype, cytoge-
netic, molecular analysis, diagnosis of EML, treatment
schedule, and outcome were recorded. The study started
in January 2001. Until January 2010, patients’ data were
periodically updated from the participating centers, centrally
verified for consistency and completeness, and subse-
quently submitted for statistical analysis. The study design
adhered to the Declaration of Helsinki and approval for this
study was obtained from the Niguarda Hospital Review
Board.
Patients were enrolled in intensive chemotherapy proto-
cols, as previously described [30]. In brief, they received a
standard induction therapy with an anthracycline-containing
regimen, most commonly the “713” regimen with cytara-
bine in 7-day continuous intravenous infusion and three
doses of anthracycline (idarubicin 12 mg/m2/day or daunor-
ubicin 60 mg/m2/day) or the “ICE” schedule, including eto-
poside 100 mg/m2/day on days 1–5.
The post-remission chemotherapy consisted of three
consolidation courses. In patients treated with the “713”
regimen, the first cycle was with high-dose cytarabine
(3,000 mg/m2 every 12 hr for 3 consecutive days, with
patients older than 50 years receiving a reduced dose at
2,000 mg/m2) and idarubicin 10 mg/m2/day on days 1 and
3, while patients treated with ICE schedule received a
NOVIA course (mitoxantrone 12 mg/m2/day on days 1–4
and cytarabine 500 mg/m2 every 12 hr for 6 doses). The
second and third consolidation courses consisted of high-
dose cytarabine.
The conditioning regimen for both autologous stem cell
transplantation (ASCT) and allogeneic stem cell transplan-
tation (allo-SCT) was with cyclophosphamide 60 mg/kg/day
for 2 days and total-body irradiation in 6 fractions of 200
cGy (1,200 cGy) or busulfan 16 mg/kg over 4 days and cy-
clophosphamide 50 mg/kg over 4 days.
Definitions and criteria for treatment response
CR was defined as less than 5% of bone marrow blasts,
regression of extramedullary disease, transfusion independ-
ency with peripheral neutrophil count greater than 1.0 3
109/L and platelet count greater than 100 3 109/L and dis-
appearance of the cytogenetic and molecular markers
[34,35]. Recurrent disease is defined as the reappearance
of more than or equal to 5% blasts in the bone marrow or
in the peripheral blood or as the appearance of a new
extramedullary site of disease in patients with a previously
documented CR.
Extramedullary disease was defined as any leukemic col-
lection outside the bone marrow and its presence was
documented either by histological, cytological, or radiologi-
cal criteria.
Overall survival (OS) was calculated from the date of diag-
nosis until death, where all living patients were censored at
the time of last contact. The duration of CR was calculated
from the date of the first CR until the date of the first relapse.
RI was calculated from the date of the first CR until the date
of the first relapse, where patients were censored at the time
of last contact or death not because of recurrent disease.
Screening of mutations in the coding region
of KIT gene
Bone marrow samples were submitted for a centralized
analysis for KIT gene mutations in exon 2, 8, 10, 11, and
17. Mutations of exon 17 were detected using sequencing
and other sensitive assays such as enzymatic digestion
with HinfI for Asp816Val and with Tsp509I for Asn822Lys
and ARMS (amplification refractory mutation system) poly-
merase chain reaction (PCR) for Asp816Tyr and Asp816His
[22,36,37]. Direct sequencing of DNA and cDNA products
was performed using Thermo Sequence Dye Terminator
sequencing reaction and ABI Prism 3100 sequencing ana-
lyzer (Applied Biosystems, Warrington, United Kingdom).
Statistical analyses
All collected variables were submitted to usual descrip-
tive methods. In particular, for continuous variables the dis-
tribution was first evaluated by the Shapiro–Wilk test, so
that normally distributed variables were summarized with
mean and standard deviation, while nonnormal variables
were summarized with median and range.
The Pearson’s chi-square test with Yates’ correction for
continuity and the Fisher’s exact test (if applicable) were
used to check the association between categorical data, af-
ter crosstabulation. Comparisons of normally distributed
continuous variables were carried out by Student’s t-test or
by Welch test (in the case of nonhomogeneous variances
between groups, previously verified by Levene’s test). The
Mann–Whitney U test was used for comparison of continu-
ous non-normally distributed variables.
The survival analysis was carried out using the Kaplan–
Meier product limit method, followed by the log-rank test, to
evaluate the possible differences in survival between groups.
Cox univariate and multivariate regression models were
also used to analyze the effects of continuous variables on
survivorship. The optimal multivariate model was chosen
TABLE I. Clinical Characteristics at Presentation of Patients with inv(16)/
t(16;16)
Parameter n5 58
Median age at diagnosis (range, yr) 42 (15–60)
Sex (male/female) 40/18
Median WBC (range, 3109/L) 24.7 (1.8–277)
Median marrow blast (range, %) 77.5 (26–95)
Extramedullary disease, no. (%) 7 (12.0)
Cytogenetic features
Without additional abnormalities (%) 43 (74.1)
No. abnormalities (%) 13* (22.4)
Including 18 2
Including 122 6
Including LOS 1
Structure abnormalities (%) 3* (5.2)
Including del(7q) 2
KIT mutational status
KIT mutated cases, no. (%) 15 (25.9)
Exon 17 12
Exon 8 2
Exon 10 1
WBC, white blood cells; LOS, losses of a sexual chromosome.
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using a backward stepwise elimination after inserting all
variables showing P< 0.20 at univariate analysis.
The receiver operating characteristics (ROC) curve was
traced to analyze the role of patients’ age on survivorship
and to search for an optimal cut-off value for age itself. For
all possible cut-off points, the total accuracy was consid-
ered together with sensitivity, specificity, positive predictive
value and negative predictive value and the cut-off choice
was made according to Youden.
Statistical analysis was done using Stata/SE 11.1 (The
StataCorp, College Station, TX). Statistical significance
was assumed for all tests with P< 0.05. The Bonferroni
method was used to adjust significance in case of multiple
comparisons.
Results
Overall results of treatments
Fifty-eight patients, aged between 15 and 60 years (me-
dian age: 42 years; male/female: 40/18), underwent treat-
ment as described and were assessed for response. CR
was obtained from 56 out of 58 (96.5%) patients. Primary
refractory disease and one infectious complication during
post-chemotherapy aplasia accounted for the two KIT-nega-
tive patients (aged 57 and 60 years, respectively) who did
not achieve CR. A toxic death was subsequently recorded
during the consolidation therapies. Twelve patients under-
went ASCT instead of the third consolidation course and
two KIT-negative patients received an allo-SCT in the first
complete remission (CR1) from a sibling donor.
The median follow-up time for patients was 50 months
based on the reverse Kaplan–Meier method. The estimated
5-year OS and RI resulted in 69.2% and 48.4%, respec-
tively, with 32 patients alive in CR1 and 11 patients alive in
second or subsequent CR (Figs. 1A and 2A; Table II).
Figure 1. Kaplan–Meier plots showing the probability of survival. (A) Adult
patients aged less than or equal to 60 years with inv(16)/t(16;16). The estimated
5-year OS resulted 69.2%. (B) KIT-negative (black line) versus KIT-positive (gray
line) patients. OS was not affected by KIT mutational status (P50.5691), with an
estimated 5-year OS of 72.1% and 62.3% for KIT-negative and KIT-positive
patients, respectively. (C) Patients aged less than 43 years (black line) or older
than or equal to 43 years (gray line). Age showed prognostic significance for OS
at a cut-off point set at 43 years (P<0.00005), with an estimated 5-year OS of
95.5% and 37.2%, respectively. OS: overall survival.
Figure 2. Kaplan–Meier plots showing the relapse incidence. (A) Adult patients
aged less than or equal to 60 years with inv(16)/t(16;16). The estimated 5-year RI
resulted 48.4%. (B) KIT-negative (black line) versus KIT-positive (gray line)
patients. No difference was seen in term of RI between KIT-negative and KIT-posi-
tive patients (P50.166), with an estimated 5-year RI of 41.8% and 65.5%,
respectively. RI: relapse incidence.
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Relapse incidence and survival after relapse
Twenty-four out of 56 patients who achieved CR experi-
enced relapse, including 4 patients who received an ASCT
in CR1. The RI plot grew up rapidly to 43.6% within 17.7
months and reached 48.4% at 38.2 months (Fig. 2A).
Twenty-three out of 24 patients underwent salvage chemo-
therapy, while 1 patient was lost at follow-up. The median
survival time after relapse was 14.7 months (range: 1.1–
92.4), with 17 (74%) patients achieving a second complete
remission (CR2) and 6 (26%) dying for resistant relapse.
Eleven patients underwent a stem cell transplantation (1
ASCT, 10 allo-SCT) in CR2. Of them, eight allo-transplanted
patients were alive and disease-free with a median CR2 du-
ration of 30.8 months (range: 1.0–91.4), and three patients
died for transplant-related mortality. The remaining six
patients who entered the CR2 received intensive consolida-
tion chemotherapy courses: four patients presented a sec-
ond relapse and three of them subsequently died from
disease progression (Table II). Overall, 11 out of 23 (47.8%)
relapsed patients are still alive and disease-free, with a me-
dian CR2 duration of 19.0 months (range: 1.0–91.4).
Incidence of KIT mutations and correlation between
KIT status and clinical characteristics
Mutational screening reported KIT gene mutations in 15
of 58 patients (25.9%): 12 (20.6%) patients showed a
D816 missense mutation (TKD816), 2 (3.4%) patients pre-
sented an Exon 8 in-frame deletion plus insertion muta-
tions, and 1 (1.7%) patient had an Exon 10 (V530I)
transmembrane mutation (Table I). Patients with KIT gene
mutations were classified as “KIT-positive” (KIT1), while
the remaining 43 patients who showed no mutations were
classified as “KIT-negative” (KIT–). Statistical analysis
showed no significant difference in terms of age
(P50.368), sex ratio (P 5 0.756), and WBC count at diag-
nosis (P50.765) between KIT1 and KIT– patients.
Seven patients out of the 58 cases included in this study
(12.0%) had EML at presentation. In all cases the EML
manifested in the form of myeloid sarcoma involving a vari-
ety of sites (spinal masses, gastrointestinal tract, lungs)
except for skin. The association between the KIT muta-
tional status and EML turned out to be not significant
(P5 0.360).
Treatment outcome by KIT mutational status
CR was achieved in 100.0% (15/15) of KIT1 patients af-
ter induction therapy. Recurrent disease was observed in 9
(60.0%) and 15 (34.9%) patients of KIT1 and KIT– groups,
respectively. No difference was seen in terms of RI
between KIT1 and KIT– patients (P50.166), with an esti-
mated 5-year RI of 65.5% and 41.8%, respectively (Fig.
2B). Similarly, OS was not affected by KIT mutational sta-
tus (P5 0.569), with an estimated 5-year OS of 62.3% and
72.1% for KIT1 and KIT– patients, respectively (Fig. 1B).
Resistant relapses (four patients) and one transplant-
related death accounted for the five KIT1 deceased
patients (Table III).
Prognostic factors for overall survival and
relapse incidence
Cox univariate and multivariate regression models were
performed to evaluate the role of different clinical variables as
predictors for relapse or survival. The following potential prog-
nostic parameters were evaluated, namely, age, sex, WBC
count at diagnosis, EML, KIT status, and presence at stand-
ard cytogenetic of trisomy of chromosome 22. For continuous
variables (age and WBC), an ROC curve analysis was per-
formed toward survival in search of possible cut-off values.
Age distribution showed an optimal cut-point at 43 years
(AUC 0.827, sensitivity 93.3%, specificity 68.3; P50.0001),
while no possible cut-off points for WBC were identified.
In univariate analyses, only age, both as continuous or
dichotomous variable with cut-off point set at 43 years,
TABLE II. Clinical Characteristics and Outcome of Patients with inv(16)/t(16;16) and Recurrent Disease
Age (Yr)/ sex Cytogenetic at diagnosis KIT status WBC, 3109/L EML
Status
at ASCT
Status at
allo-SCT Outcome
Survival
(months)
24/M 46,XY,inv(16)(p13q22) w/t 169,8 Absent ND ND A/1st rel 16,6
26/M 46,XY,inv(16)(p13q22),
t(11;12)
V503I 7,6 Absent ND ND A/2nd CR 97,9
29/F 46,XX,inv(16)(p13q22) D816V 11,1 Gastric
mass
ND 2nd CR A/2nd CR 46,7
32/F 46,XY,inv(16)(p13q22) w/t 52,3 Absent ND 2nd CR A/2nd CR 34,3
36/M 46,XY,inv(16)(p13q22) w/t 19,0 Absent ND 2nd CR A/2nd CR 74,8
36/M 46,XY,inv(16)(p13q22) w/t 30,4 Absent ND 2nd CR A/2nd CR 70,5
36/M 46,XY,inv(16)(p13q22) w/t 11,3 Absent ND ND A/2nd CR 21,1
36/M 46,XY,inv(16)(p13q22) D816V 141,0 Absent 1st CR 2nd CR A/2nd CR 54,0
38/F 46,XX,inv(16)(p13q22) Exon 8 4,4 Absent ND 2nd CR A/2nd CR 49,6
39/M 47,XY,inv(16)(p13q22),16 w/t 96,2 Absent ND 2nd CR A/2nd CR 64,3
42/M 46,XY,inv(16)(p13q22) w/t 11,7 Mesenteric
mass
1st CR 2nd CR A/2nd CR 107,2
56/F 46,XX,inv(16)(p13q22) w/t 13,4 Absent 1st CR ND A/3rd CR 50,0
43/F 46,XX,inv(16)(p13q22) w/t 130,0 Absent ND 2nd CR D/TRM 2nd CR 27,1
46/M 46,XY,inv(16)(p13q22) w/t 23,8 Absent ND 2nd CR D/TRM 2nd CR 52,6
18/M 46,XY,inv(16)(p13q22) D816V 12,8 Absent 2nd CR ND D/TRM 2nd CR 28,8
60/M 46,XY,inv(16)(p13q22) w/t 27,7 Absent ND ND D/1st res rel 11,2
47/M 47,XY,inv(16)(p13q22),
122,del(7)
D816H 12,3 Absent ND ND D/1st res rel 29,8
54/F 48,XX, inv(16)(p13q22),
18,121
w/t 49,8 Absent ND ND D/1st res rel 7,1
52/M 46,XY,inv(16)(p13q22) w/t 10,9 Ileal mass ND ND D/1st res rel 10,3
55/M 46,XY,inv(16)(p13q22) D816V 150,0 Absent ND ND D/1st res rel 14,4
58/F 46,XX,inv(16)(p13q22) D816V 122,0 Absent ND ND D/1st res rel 11,8
50/M 46,XY,inv(16)(p13q22) w/t 12,0 Absent 1st CR ND D/2nd rel 28,6
60/M 48,XY,inv(16) (p13q22),
19,122
w/t 14,9 Absent ND ND D/2nd res rel 22,4
54/M 46,XY,inv(16)(p13q22) D816V 110,0 Absent ND ND D/2nd res rel 26,8
allo-SCT, allogeneic stem cell transplantation; ASCT, autologous stem cell transplantation; CR, complete remission; EML, extramedullary leukemia; WBC, white
blood cells; ND, not determined; w/t, wild type; TRM, transplant related mortality.
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showed prognostic significance for OS (P< 0.00005) (Fig.
1C), whereas no statistical significance was found for all
the other variables. When combined in the multivariate
analyses, only age both as continuous or dichotomous vari-
able was a significant part of the Cox model and proved to
be an independent risk factor for OS (P <0.001). Any
increase of 1 year in age led to a 15% increase
(P<0.0005) of the hazard of death, while being 43 years
old or more implied a hazard ratio of 47.41 (95% CI; 4.87–
461.39; P5 0.004), adjusting by WBC, EML, andKIT muta-
tional status (Table IV).
In the multivariate Cox model with backward elimination
of factors, WBC emerged as an independent risk factor for
RI (P50.017) and any 1.0 3 109/L increment of WBC
meant a 1.1% increase of the hazard of relapse (95% CI;
1.002–1.020; P50.017), adjusting by age and KIT muta-
tional status (Table IV). KIT mutations showed a trend for
RI but did not reach a significative value (P5 0.069).
Discussion
In this study, we have evaluated the impact of clinical
and genetic features on the prognosis of de novo AML with
inv(16)/t(16;16) in 58 patients with age less than or equal
to 60 years, treated according to standard chemotherapy
protocols. Overall, we observed a high CR rate (96.5%), a
RI of 48.4% at 38.2 months after the first CR and, an esti-
mated 5-year OS of 69.2%, according to outcome data
reported in the recent literature. In this relative large cohort
of homogeneously treated patients, we found that only
WBC at presentation and age emerged as an independent
risk factor for relapse (P5 0.017) and OS (P< 0.001),
respectively.
A high-peripheral WBC count together with a raised se-
rum LDH, the presence of hepatosplenomegaly, and EML,
may reflect an increased tumor burden in AML even in the
setting of “good risk” acute leukemias, such as acute pro-
myelocytic leukemia or CBF-AML [19,38–40]. In AML with
inv(16), Delaunay et al. [20] reported that bad prognosis
factors for CR achievement were a high WBC count, with
an optimal cut-off point at 120 3 109/L, and lower platelet
count. Martin et al. [19], in a small study, found that pre-
senting WBC count had a significant negative influence on
disease-free survival. Our data are substantially in line with
reported data, therefore we found an increase of 1.1% haz-
ard of relapse for each 1.0 3 109/L increment of WBC
count. However, we were not able to identify any possible
WBC cut-off value by means of the ROC analysis.
Activating KIT mutations are frequently found in CBF leu-
kemia [41]. We recorded here an incidence of 25.9% of
KIT mutations, with most patients showing D816 missense
mutations (Table I). From this aspect, it is of interest that
expression levels of both KIT mRNA and proteins is much
higher in CBF-AML, with either wild type or mutant KIT,
than in leukemia cells negative for CBF rearrangements.
Moreover, we recently reported that CBF genetic abnormal-
ities, in addition to directly targeting and down-regulating
the expression of hematopoietic protein-coding genes con-
taining AML1 consensus sequences, can target microRNA
genes (Mir222/221) involved in the regulation of the KIT re-
ceptor leading to KIT overexpression in CBF-AML [42]. Fur-
thermore, it has been postulated that mutations of the KIT
gene may drive the WBC proliferation in CBF leukemia.
Recently, Luck et al., showed that KIT mutations confer a
distinct gene expression signature in CBF-AML and that
one of the most significantly differentially expressed gene
is LRP6 that is essential for noncanonical WNT5A signaling
and thus for the maintenance of stem and progenitor cells
[43,44]. Authors suggested that the different gene profiling
may lead to an enhancement of proliferation in the KIT-
mutated cases, which may be reflected in the higher blast
counts of those patients [43]. The clinical observations that
affected patients with t(8;21) appear to have a higher WBC
count and WBC-index at presentation and a higher fre-
quency of EML might support this hypotheses [30,39,45].
However, despite these reports on AML with t(8;21), we
did not find any difference in WBC count (P5 0.765) and
incidence of EML (P5 0.360) between the 15 KIT1 and the
43 KIT– cases harboring the inv(16)/t(16;16) recruited in
this study. Similarly, regarding the impact on outcome, this
TABLE III. Clinical Characteristics and Outcome of KIT-Positive Patients with inv(16)/t(16;16)
Age (Yr)/ Sex
Cytogenetic
at diagnosis KIT status WBC, 3109/L EML
Status at
ASCT
Status at
allo-SCT Outcome
Survival
(months)
18/M 46,XY,inv(16)(p13q22) D816V 12.8 Absent 2nd CR ND D/TRM 2nd CR 28,8
20/M 47,XY,inv(16)(p13q22),122 D816Y 18.0 Absent ND ND A/1st CR 39,6
26/M 46,XY,inv(16)(p13q22),t(11;12) V503I 7.6 Absent ND ND A/2nd CR 97,9
29/F 46,XX,inv(16)(p13q22) D816V 11.1 Gastric mass ND 2nd CR A/2nd CR 46,7
36/M 46,XY,inv(16)(p13q22) D816V 141.0 Absent 1st CR 2nd CR A/2nd CR 54,0
38/F 46,XX,inv(16)(p13q22) Exon 8 4.4 Absent ND 2nd CR A/2nd CR 49,6
38/M 47,XY,inv(16)(p13q22),18 D816Y 13.6 Mesenteric
mass
ND ND A/1st CR 71,0
41/M 46,XY,inv(16)(p13q22) D816F 13.2 Absent ND ND A/1st CR 19,6
47/M 47,XY,inv(16)(p13q22),122,del(7) D816H 12.3 Absent ND ND D/1st res rel 29,8
50/F 46,XY,inv(16)(p13q22) Exon 8 277.5 Lung ND ND A/1st CR 38,2
51/M 46,XY,inv(16)(p13q22),del(7) D816F 74.2 Absent ND ND A/1st CR 5,4
53/M 46,XY,inv(16)(p13q22) D816V 27.3 Absent ND ND A/1st CR 141,5
54/M 46,XY,inv(16)(p13q22) D816V 110.0 Absent ND ND D/2nd res rel 26,8
55/M 46,XY,inv(16)(p13q22) D816V 150.0 Absent ND ND D/1st res rel 14,4
58/F 46,XX,inv(16)(p13q22) D816V 122.0 Absent ND ND D/1st res rel 11,8
allo-SCT, allogeneic stem cell transplantation; ASCT, autologous stem cell transplantation; CR, complete remission; EML, extramedullary leukemia; WBC, white
blood cells; ND, not determined; TRM, transplant related mortality.
TABLE IV. Multivariate Analysis for OS and RI
Variable HR P 95% CI
Overall survival (P> v250.0003)
AGE 1.148 0.0003 1.065 1.237
WBC 1.008 0.252 0.994 1.023
EML 4.605 0.090 0.787 26.930
KIT 1.354 0.651 0.364 5.038
Relapse incidence (P> v250.0271)
AGE 1.031 0.105 0.994 1.070
WBC 1.011 0.017 1.002 1.020
KIT 2.172 0.069 0.940 5.017
EML, extramedullary leukemia; WBC, white blood cells; AGE, age at diagno-
sis. Significant P-values are showed in bold.
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study showed that KIT mutations did not reach a significa-
tive value as independent prognostic factor for relapse and
survival neither in the multivariate nor in the Kaplan–Meier
analysis, in contrast to those reported in adult patients with
t(8;21) (Figs. 1B–2B; Tables III and IV) [24,26–28,30–32].
Accumulating evidence suggests that a high degree of
similarity is identified between the two major subtypes of
CBF leukemias. However, important differences on clinical
and biological ground are reported [1,2]. A recent study
using Drosophila as a model showed that AML1-ETO-
expressing precursor cells express high levels of reactive
oxygen species (ROS), and that ROS plays a central role
in the proliferation of these precursors [46]. As for CBFb–
MYH11 leukemia, gene expression profiling of AML-M4
subtype suggested a highly activated NF-kB pathway in
inv(16) patients [47]. Given that these pathways, particu-
larly Notch, Wnt, and Cox/PGE2 signaling, are essential for
stem cell self-renewal, they could contribute to a different
transforming activity of AML1-ETO and CBFb–MYH11 in
CBF-AML.
Although our data suggest that a high WBC count is an
unfavorable prognostic factor, because it increases the risk
of relapse in multivariate analysis, it shows no significant
effect on overall survival. In fact, after salvage and subse-
quent therapy including allo-SCT, we found that 11 out of
23 relapsed patients who underwent salvage chemotherapy
are still alive and disease-free, with a median CR2 duration
of 19 months.
In this study, only age as continuous or dichotomic value,
with a best calculated cut-off point at 43 years, emerges as
a prognostic factor affecting survival in both univariate or
multivariate analysis. It is to be noted that, among the 30
patients aged 42 years or younger, we recorded only one
death (transplant related), leading to a Kaplan–Meier plot
of 95.5% for OS (P<0.00005) (Table II; Fig. 1C). By con-
trary, focusing on 28 patients aged 43 years or older, we
recorded 14 deaths (2 early deaths, 1 death in aplasia, 2
deaths for transplant-related complications, and 9 for first
or second resistant relapse). Overall, 50% of patients aged
43 years or older are disease-free at 27.1 months (Table II;
Fig. 2C).
Our data confirm that the strategy to perform an alloge-
neic SCT in CR >1 lead to encouraging results. In fact, of
the 10 patients allo-transplanted while in second CR, 8
(80%) are alive and disease-free, with a median follow-up
of 30.8 months. As in our study, Kuwatsuka et al., of 66
patients with inv(16) undergoing allo-SCT, reported an OS
of 86% at 3 years in CR2 or CR3 and identified only age to
be a significant prognostic factor. The Japanese study con-
cluded that allo-SCT is not necessarily recommended for
inv(16) in CR1 and that inv(16) patients who received an
allo-SCT not in CR did significantly better than those with
t(8;21) [2]. Furthermore, a French survey reported that
age, with a best cut-off at 35 years, was the only factor for
shorter disease-free survival in AML with inv(16) [20].
It has been repeatedly demonstrated that prognosis wor-
sens with increasing age in AML [48,49]. This may reflect
concurrent comorbidities in addition to different disease
biology such as multidrug resistance protein (MDR-1) posi-
tivity or stem cell phenotype adversely affecting both attain-
ment of remission and refractory relapse risk [49,50].
Paschka et al. reported that in inv(16) patients the cumu-
lative incidence of relapse (CIR) was higher for KIT-positive
patients, especially if presenting exon 17 mutation, com-
pared with KIT-negative patients (5-year CIR 80% vs. 29%;
P50.002). Furthermore, the authors reported that KIT
mutations predicted worse survival when adjusted for sex
[24]. Anyway, it has to be noted that in the CALGB study
the KIT-mutated patients were significantly older (median
age: 38 vs. 49 years; P<0.001) and were more frequently
male (P< 0.05) compared with nonmutated patients. More-
over, in the reviewed literature, all the focused studies on
the prognostic significance of KIT mutations in the CBFb-
MYH11 adult patients have been unable to demonstrate
any role of such mutations on survival; furthermore, to our
knowledge, all studies but one [26] do not show any influ-
ence of KIT mutations on relapse [27,30–32].
All the results reported in these different studies are
based on a relatively small population, principally because
of the fact that AML is a rare disease and that the CBFb
subtype accounts for about 5–8% of adults with de novo
AML. In a 9-years period (January 2001–January 2010),
we considered 58 patients aged less than or equal to 60
years belonging from 8 Italian centers. At present, this is
one of the studies with the largest number of adult CBFb
AML patients, second only to the one of Paschka and col-
leagues (counting 61 patients). Incrementing the number of
patients surely would be of interest, but when it results in
an excessive accrual time statistical analysis it is more
likely to be biased.
In conclusion, while the prognostic significance of KIT
mutations remains unclear with several studies yielding
contrasting results [24,26,27,30–32], our data showed that
only “old” prognostic factors, such as age and the WBC
count at diagnosis, are important predictors of outcome in
AML adult patients with inv(16)/t(16;16).
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